A GLP-1 Trial in the Lancet Cut Heavy Drinking Days by Fourteen Points
108 patients, 26 weeks of semaglutide plus CBT yielded a 13.7-point cut in heavy drinking days — the first RCT supporting GLP-1 for alcohol use disorder.
The news. The narrative. The timeline.
Bureau: Chicago
108 patients, 26 weeks of semaglutide plus CBT yielded a 13.7-point cut in heavy drinking days — the first RCT supporting GLP-1 for alcohol use disorder.
Utah at 663 cases — 37 in the last three weeks versus 121 in the prior three — while Travis County, Texas confirmed its first 2026 case on May 7 and Michigan now has 7 cases across four counties.
A 62-person Cork RCT in Nature Communications — 14 days off coffee, then 21 days of caffeinated or decaf — shifted the gut similarly in both arms, implicating chlorogenic acids over caffeine.
Taiho's Inqovi plus venetoclax — FDA-approved May 13 for newly diagnosed AML in patients 75+ or otherwise ineligible for intensive induction — is the first all-oral combination for this population.
Atlanta's noon Thursday refresh meets a slowing Utah curve and a widening out-of-state map, with Travis County the new entry.